Efficacy

Skilarence (Dimethyl Fumarate) for Psoriasis

Skilarence, containing the active ingredient dimethyl fumarate, is an oral systemic treatment approved for moderate to severe plaque psoriasis. The efficacy of Skilarence in the treatment of psoriasis has been demonstrated in clinical trials. Patients treated with Skilarence have shown significant improvement in Psoriasis Area and Severity Index (PASI) scores, a measure of the severity and extent of psoriasis, compared to those receiving placebo. The therapeutic effects of Skilarence are attributed to its anti-inflammatory and immunomodulatory properties, which help to reduce the scaling, thickness, and redness of psoriatic plaques.

Long-term studies have also indicated sustained efficacy and a favorable safety profile for Skilarence in psoriasis management. The drug has been found to maintain its effectiveness over extended periods, with continuous treatment leading to further improvements or stable disease control in a significant proportion of patients. However, as with any medication, the response to Skilarence can vary among individuals, and some patients may experience more benefit than others.

Skyrizi (Risankizumab) for Psoriasis

Skyrizi, with the active ingredient risankizumab, is a biologic injectable medication specifically designed for the treatment of moderate to severe plaque psoriasis. As a monoclonal antibody, Skyrizi targets interleukin-23 (IL-23), a cytokine that plays a key role in the inflammatory processes associated with psoriasis. Clinical trials have shown that Skyrizi is highly effective in achieving clear or almost clear skin as assessed by PASI scores. A significant majority of patients receiving Skyrizi achieve PASI 90, indicating a 90% reduction in PASI scores, which is considered a high level of clearance of psoriatic lesions.

The efficacy of Skyrizi is not only marked by the significant skin clearance but also by the durability of response. Patients have been observed to maintain treatment responses with continued dosing, which is typically administered once every 12 weeks after the initial dosing phase. The robust clinical data supporting Skyrizi's efficacy make it a strong treatment option for long-term management of moderate to severe plaque psoriasis. Nevertheless, individual results may vary, and healthcare providers consider various factors when determining the most appropriate treatment for their patients.